"text","instanceType","description","name","id","label","uuid:ID"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective","Main objective","OBJ1","Objective_1","","051bff4a-0d8e-4af2-b35e-8594e49e506f"
"To document the safety profile of the xanomeline TTS.","Objective","Safety","OBJ2","Objective_2","","8ba2a1cd-70e1-4d0d-bf2b-efeeae9fa4fb"
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective","Behaviour","OBJ3","Objective_3","","f9c72967-254b-4fba-ac59-0d2ba50bee7b"
"To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","Objective","","OBJ4","Objective_4","","1b56aa5d-c848-472c-8b9d-e77d7e7ddc55"
"To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","Objective","","OBJ5","Objective_5","","fa04b812-d2d7-49f5-9183-a6b444d951e2"
"To assess the treatment response as a function of Apo E genotype.","Objective","","OBJ6","Objective_6","","0b045a0c-772b-492a-89d7-05777239e6fc"
